A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alan Boyd, MD, FFPM
Actinogen Medical
Study Director - Bill Ketelbey, MD
Actinogen Medical
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Central Coast Neurosciences Research
Central Coast, New South Wales, Australia
- St Vincent'S Hospital Sydney
Darlinghurst, New South Wales, Australia
- Kara Institute of Neurological Diseases
Macquarie Park, New South Wales, Australia
- Medical & Cognitive Research Unit, Heidelberg Repatriation Hospital - Austin Health
Heidelberg West, Victoria, Australia
- Australian Alzheimer'S Research Foundation
Nedlands, Western Australia, Australia
- the Research Institute for the Care of Older People
Bath, Combe Park, United Kingdom
- Manchester Mental Health & Social Care Trust - Dementia Research Office - Park House North Manchester General Hospital
Manchester, Lancashire, United Kingdom
- West London Mental Health Trust
Isleworth, London, United Kingdom
- St Pancras Clinical Research
Kings Cross, London, United Kingdom
- Institute of Clinical Sciences, Queen'S University Belfast
Belfast, Northern Ireland, United Kingdom
- Centre for Clinical Brain Sciences, Centre for Dementia Prevention, the University of Edinburgh
Edinburgh, United Kingdom
- Tucson Neuroscience Research, Llc
Tucson, Arizona, United States
- National Research Institute
Los Angeles, California, United States
- Pcnd Neuroscience Research Institute
Poway, California, United States
- Pacific Research Network, Inc.
San Diego, California, United States
- Research Alliance Inc.
Clearwater, Florida, United States
- the Neurology Research Group, Llc
Miami, Florida, United States
- Compass Research Llc
Orlando, Florida, United States
- Imic, Inc.
Palmetto Bay, Florida, United States
- Atlanta Center for Medical Research
Atlanta, Georgia, United States
- Neurostudies.Net, Llc
Decatur, Georgia, United States
- the Neurocognitive Institute
Mount Arlington, New Jersey, United States
- Richmond Behavioral Associates
Staten Island, New York, United States
- Pmg Research of Rocky Mount, Llc
Rocky Mount, North Carolina, United States
- the Clinical Trial Center
Jenkintown, Pennsylvania, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Mar 2017
- Primary completion
- 15 Mar 2019
- Completion
- 15 Mar 2019
- Last update posted
- 3 Feb 2025
- Registered enrollment
- 185
- Registry id
- NCT02727699
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.